Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center, has been honored with the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH, for her groundbreaking research to develop and advance innovative cell therapies for cancer using natural killer (NK) cells.
Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers at the UC Davis Comprehensive Cancer Center have discovered that using gene therapy to inhibit a specific protein, galectin 1, can shrink liver cancer tumors in an animal model.
SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.
George Demetri, MD, director of the Sarcoma Center at Dana-Farber Cancer Institute, is being awarded the prestigious J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA).
The Latin American and Caribbean Society of Medical Oncology (SLACOM) and National Comprehensive Cancer Network (NCCN) host the Latin American Regional Breast Cancer Summit: Advocating and Implementing Guideline-Concordant Cancer Care for Patients. Esteemed experts from Argentina, Brazil, Mexico, Columbia, Peru, and the United States present challenges, barriers, and potential solutions for improving access to guideline-concordant breast cancer care in the Latin American region.
Moffitt Cancer Center has received a $3.6 million grant from the National Institute of Dental and Craniofacial Research (U01DE033329) to further groundbreaking research that has unveiled a promising noninvasive diagnostic biomarker panel for the early detection of oropharyngeal cancer.
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.
Researchers in Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have been working to better understand what drives melanoma brain metastasis.
Memorial Sloan Kettering Cancer Center (MSK) and NMDP/Be The Match® today announced the launch of the “American Symphony: Become a Lifesaver” campaign to increase registration of blood stem cell and marrow donors to the national registry and improve access to blood stem cell transplants.
A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective in patients with locally advanced pancreatic cancer, yielding a higher progression-free survival (PFS) and overall response rate (ORR).
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12. This year’s ASH meeting will include oral and poster presentations, workshops, and educational sessions for hematology professionals.
Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023.
Robert A. Winn, MD, president of the Association of American Cancer Institutes (AACI) and director of VCU Massey Comprehensive Cancer Center, has appointed two community advocates to the steering committee of his AACI presidential initiative, Inclusive Excellence.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix.
The Association of American Cancer Institutes (AACI) supports President Biden’s nomination of W. Kimryn Rathmell, MD, PhD, MMHC, as the next director of the National Cancer Institute (NCI).
Akshu Balwan, MD, breathes easier these days because The University of New Mexico Comprehensive Cancer Center launched a new comprehensive lung cancer screening clinic as part of the institution's lung cancer screening program.
Patients with advanced prostate cancer with tumors harboring RB1 gene loss or neuroendocrine features often have a poor prognosis and limited treatment options.
A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
The James P. Allison Institute at MD Anderson hosted its inaugural scientific symposium on Nov. 10, bringing together more than 400 leading scientists in immunotherapy and immunobiology.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
Howard Meyers, of Dallas, Texas, a member of The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), has committed $25 million to The University of Texas MD Anderson Cancer Center to establish the Meyers Institute for Oncology Nursing.
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the most advanced computational and data science approaches with the institution’s extensive scientific and clinical expertise to significantly improve patient’s lives by transforming cancer care and research.
Elevating the combined strengths of the nationally recognized cancer center and the state’s largest academic health system will revolutionize care in New Jersey and beyond.
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
The Association of American Cancer Institutes (AACI) congratulates Monica Bertagnolli, MD, on her U.S. Senate confirmation today as the next director of the National Institutes of Health (NIH).
The morning of Sunday Oct. 29th wasn’t too different for Albuquerque resident Nicholas Juskiewicz and Brandon Behrens, MD, a trauma surgeon at The University of New Mexico Hospital. Jusckiewicz put on his cycling kit and headed to Albuquerque’s Old Town area to start the Day of the Tread 61-mile bicycle ride.
MD Anderson and Jazz Pharmaceuticals announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
As more cancer care is delivered in outpatient treatment centers such as Fred Hutchinson Cancer Center in Seattle, the burden on cancer caregivers is evolving. Fred Hutch has developed a package of stories to support and celebrate the role of caregivers in cancer care.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational, and clinical cancer research from MD Anderson experts. irectly into the liver for patients with metastatic uveal melanoma.
For Gladys Tsao-Wu, MD, and Jennifer Chan, MD, reconstruction is as much about helping patients recover emotionally as it is about physical restoration. For over a decade, the two surgeons have been a team, helping breast cancer survivors in New Mexico.
SEATTLE — November 2, 2023 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. November is Lung Cancer Awareness Month. If you’re looking for resources, see our media tip sheet and contact [email protected] to set up interviews.
Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.
Domestic violence went down or stayed the same during the first 10 months of the COVID-19 pandemic in five major U.S. cities. However, domestic violence involving firearms increased in three of those cities, according to a new UC Davis study published in the Journal of Family Violence.
National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available at NCCN.org/patientguidelines.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include positive results from a Phase I trial for patients with TP53-mutant acute myeloid leukemia, a novel machine learning platform to identify cancer biomarkers from liquid biopsies, a tumor-specific multi-microRNA delivery system to improve treatment outcomes in glioblastoma, a combination strategy to overcome treatment resistance in KRAS-mutated pancreatic cancer, and a new target for improving treatment response in patients with stomach cancer that has metastasized to the peritoneal cavity.
A study by UC Davis Health endocrinology researchers shows a high prevalence of thyroid cancer among transgender female veterans, the first evidence of such a disparity.
In order to grow and train future clinical and translational scientists, The University of Kansas Cancer Center has received a $2.4 million grant from the National Cancer Institute (NCI).
As Lung Cancer Awareness Month begins in November, experts at Fred Hutchinson Cancer Center remain committed to advancing early screening, helping people quit smoking and developing new ways to detect and treat lung cancer.
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
RSS